Zyprexa (olanzapine) Mar 2004

Audience: Neuropsychiatric healthcare professionals

FDA and Lilly notified healthcare professionals of revision to the WARNINGS section of labeling, describing the increased risk of hyperglycemia and diabetes in patients taking Zyprexa. FDA has asked all manufacturers of atypical antipsychotic medications, including Lilly, to add this Warning statement to labeling.

[March 2004 - Letter - Lilly]
[January 2004 - Revised Label - Lilly]